A swimmer asked for faster treatments. Three months is now the deadline for an answer
What happened
On 14 October 2026, the Prime Minister announced four changes meant to speed up the journey from brain cancer research to brain cancer treatment. The announcement followed a meeting at Downing Street with Archie Goodburn, a 25-year-old swimmer who has inoperable brain cancer. He had spoken about his situation on BBC Breakfast, and the meeting came after that. Four things were promised. First, an expert review. Professor Anthony Chalmers, who chairs the Brain Tumour Group within the UK Collaborative for Cancer Clinical Research, will lead it. It has to report within three months. Its job is to look at what has actually changed for patients since the government's brain tumour review in 2018, and what is still getting in the way. Second, a national action plan will follow that review, aimed at moving new treatments from the laboratory to patients faster. Third, the Department of Health and Social Care will appoint a national brain cancer clinical lead. That is one named person with responsibility for this area. Fourth, the Prime Minister asked the Medicines and Healthcare products Regulatory Agency to finish its review of the rules for orphan drugs in two years rather than three. Orphan drugs are medicines for rare conditions, where the number of patients is small and companies often struggle to make the sums work. Alongside this, patients, families and charities will help design a push to get more people into clinical trials, and the Health and Social Care Secretary will host a roundtable with researchers, clinicians and charities. Prime Minister Andy Burnham said: "Archie is an inspiration to us all, and I am determined to deliver the change patients and their families deserve." Health and Social Care Secretary Yvette Cooper said: "We owe it to every family facing this devastating disease to do better."
Why this matters
Brain cancer is not one of the common cancers. In England in 2023, malignant brain cancer was recorded as the cause of 3,792 deaths, out of 138,578 deaths from all malignant cancers excluding non-melanoma skin cancer. That is roughly 2.7 per cent. But the numbers hide something. Of those 3,792 deaths, 278 were in people under 40. Across all cancers, only 1,711 deaths were in the under-40s. So brain cancer makes up a small share of cancer deaths overall, and a much larger share of cancer deaths in younger adults. That is part of why families and charities have pushed so hard on this. It is also why survival has been such a sore point. Many cancers have seen big gains over the past thirty years. Brain tumours have seen far less. The other reason this matters is the shape of the promise. A review with a three-month deadline is unusual. Most reviews are open-ended. A named clinical lead is also a real change, because it gives families someone to hold to account rather than a department.
What the evidence actually says
It is worth being clear about what has and has not happened here. What has happened: a review has been commissioned, a plan has been promised, a post will be created, and a regulator has been asked to work faster. None of these is a new treatment. What has not happened: no medicine has been approved, no trial has reported, and no patient's care changes this week because of the announcement. The money already in the system is real and verifiable. In January 2026 the government announced £25 million for the NIHR Brain Tumour Research Consortium, with a focus on closing the gap between laboratory work and clinical practice. The National Institute for Health and Care Research currently supports 59 brain tumour studies, 35 of which are clinical trials. Cancer Research UK says it has invested over £116 million in brain tumour research in the last decade. So the research base exists. The complaint from charities has been that getting from a promising laboratory result to a treatment a patient can actually have takes too long, and that brain cancer has a particular problem: tumours sit behind the blood-brain barrier, which keeps many drugs out, and trials are harder to fill because the patient numbers are smaller. The orphan drug change is the most concrete item. The Rare Cancers Act 2026 requires that review, and shortening it from three years to two is a measurable commitment with a date attached. Several brain cancer charities issued a joint statement welcoming the commitments: Brainstrust, Brain Tumour Research, Brain Tumour Support, The Brain Tumour Charity and the Tessa Jowell Brain Cancer Mission. Michelle Mitchell, chief executive of Cancer Research UK, called it an important step. That is broad agreement from the organisations closest to patients, which is worth something. It is not the same as proof that outcomes will improve.
Practical advice
If brain cancer affects you or someone close to you, a few things are worth knowing. Ask about clinical trials, and ask early. There are 35 brain tumour clinical trials currently supported by the NIHR. Your consultant or clinical nurse specialist can tell you whether any are open to you, and the Be Part of Research service lets you search yourself. Being in a trial is not a last resort, and it does not mean giving up standard care. Know the symptoms that need checking. Persistent headaches that are worse in the morning or when you cough or bend, new seizures in an adult, changes to your vision, weakness on one side, or changes in personality or memory that family notice before you do. Most of these turn out not to be a brain tumour. They still deserve a prompt appointment. Use the charities. Brainstrust, The Brain Tumour Charity and Brain Tumour Support all run free support lines staffed by people who do this every day. They can help you prepare questions for an appointment, which is often the difference between a useful consultation and a blur. Take someone with you to appointments, and write things down. Two people remember more than one. Treat the three-month deadline as something to watch. The review is due to report by roughly mid-January 2027. If you want to follow it, the findings are also being shared with the All-Party Parliamentary Group on Brain Tumours.
What to know
On 14 October 2026 the Prime Minister announced four steps on brain cancer: an expert review led by Professor Anthony Chalmers reporting within three months, a national action plan to follow, a new national brain cancer clinical lead at the Department of Health and Social Care, and a request to the MHRA to complete its orphan drug review in two years instead of three. The announcement followed a Downing Street meeting with Archie Goodburn, a 25-year-old swimmer with inoperable brain cancer. Existing commitments include £25 million for the NIHR Brain Tumour Research Consortium announced in January 2026. The NIHR supports 59 brain tumour studies, including 35 clinical trials. Cancer Research UK has invested over £116 million over the past decade. In England in 2023, malignant brain cancer accounted for 3,792 deaths, including 278 in people under 40. Nothing about anyone's current treatment changes because of this announcement. The things to watch are the review in three months and the appointment of the clinical lead. Sources: GOV.UK (Prime Minister's Office), "Brain cancer patients to see faster development of new treatments", 14 October 2026, https://www.gov.uk/government/news/brain-cancer-patients-to-see-faster-development-of-new-treatments; GOV.UK (MHRA), "MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines", 14 October 2026, https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency; NICE, "Patients to get new medicines up to six months sooner under new joint MHRA-NICE approval process", 2026, https://www.nice.org.uk/news/articles/patients-to-get-new-medicines-up-to-six-months-sooner-under-new-joint-mhra-nice-approval-process This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. If you are worried about symptoms, contact your GP, or call 999 if someone has a first seizure or sudden weakness or confusion.
Related articles
47% stayed off, 14% called anyone: what 68,000 surveys say about how we handle flu
On 15 October 2026, the UK Health Security Agency (UKHSA) published new findings about what people actually do when they come down with flu-like symptoms. The…
One dose, not two: what WHO's advisers have just said about the HPV jab
The World Health Organization's expert vaccine panel has changed its advice on the HPV jab. The panel is called SAGE, short for the Strategic Advisory Group of…
3.5 million deaths a year, and no level of it is safe
On 15 October 2026, the World Health Organization (WHO) published an update calling on countries to speed up action against lead poisoning. It came just before…